glp 1 and ketosis Beyond GLP-1 Agonists: An Adaptive Ketogenic–Mediterranean Protocol to Counter Metabolic Adaptation in Obesity Management Ketogenic Diets for Body Weight

M., Nagata, Y

Bi-Est allows prescribers to provide a bioidentical estrogen preparation with dose flexibility not available in commercial fixed-dose products

Of those conditions, a common comorbidity in women with menopause is closely linked to the process of CKD development, which increases mortality (Kattah et al., 2018

Autophagy is essential to suppress cell stress and to allow BCR-Abl-mediated leukemogenesis

September 12, 2025

--- Here are some potential actions covered in the article for payers and employers to take as a result of this shift: Update formulary tiers and step therapy policies (consider the impact on comorbidities) Support members transitioning off GLP-1s after reaching their goals Create differentiated access pathways based on patient risk profiles Monitor realworld outcomes beyond A1C (cardiovascular, renal, adherence) Model the downstream impact on generics and legacy therapies --- Commercial plans are accelerating GLP-1 uptake and favoring the simplicity of a single therapy